Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-017463
Filing Date
2022-11-10
Accepted
2022-11-10 16:59:31
Documents
75
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rvlp-20220930x10q.htm   iXBRL 10-Q 1620585
2 EX-31.1 rvlp-20220930xex31d1.htm EX-31.1 11175
3 EX-32.1 rvlp-20220930xex32d1.htm EX-32.1 8025
  Complete submission text file 0001558370-22-017463.txt   6696217

Data Files

Seq Description Document Type Size
4 EX-101.SCH rvlp-20220930.xsd EX-101.SCH 54147
5 EX-101.CAL rvlp-20220930_cal.xml EX-101.CAL 68646
6 EX-101.DEF rvlp-20220930_def.xml EX-101.DEF 216100
7 EX-101.LAB rvlp-20220930_lab.xml EX-101.LAB 447214
8 EX-101.PRE rvlp-20220930_pre.xml EX-101.PRE 350223
69 EXTRACTED XBRL INSTANCE DOCUMENT rvlp-20220930x10q_htm.xml XML 1049444
Mailing Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807
Business Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807 9088091300
RVL Pharmaceuticals plc (Filer) CIK: 0001739426 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38709 | Film No.: 221378254
SIC: 2834 Pharmaceutical Preparations